A PLASMIC score, which is a validated clinical prediction tool used to rapidly estimate the probability of ADAMTS13 deficiency in adults presenting with suspected TTP, was used to evaluate the next step of management. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.